Sarilumab vs placebo or usual care
Clinical improvement D60 or above · people with mild/moderate/severe/critical COVID‐19
It is very uncertain whether sarilumab changes clinical improvement D60 or moree compared with standard care/placebo (very low certainty).
1 finding from 1 review
- Interleukin‐6 blocking agents for treating COVID‐19: a living systematic review 2023 · Cochrane Headline outcomes onlyRR 1.22 [0.91, 1.63]2 studies · 239 participantsVery low